Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Transmission studies have suggested that an optimal human immunodeficiency virus type 1 (HIV-1) vaccine should induce both neutralizing antibodies and cytolytic T cells to eliminate free virus and infected cells. A phase I trial in healthy HIV-1-seronegative persons was conducted with a combination...

Cijeli opis

Spremljeno u:

Bibliografski detalji
Izdano u:	Proc Natl Acad Sci U S A
Glavni autori:	Cooney, E L, McElrath, M J, Corey, L, Hu, S L, Collier, A C, Arditti, D, Hoffman, M, Coombs, R W, Smith, G E, Greenberg, P D
Format:	Artigo
Jezik:	Inglês
Izdano:	National Academy of Sciences 1993
Teme:	Research Article
Online pristup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC45984/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8446603/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.90.5.1882
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Slični predmeti